Stock Price Plummets! Innovative Drug Leader Faces "Clearing-Out Style" Reduction by Two Shareholders

Today (March 17), major market indices opened higher across the board. In the trading session, the large financial sector surged collectively, insurance stocks rose broadly, with New China Insurance up over 4%, China Pacific Insurance and Ping An Insurance up over 3%. Brokerage firms like Guosen Securities, GF Securities, and Huatai Securities gained over 3%. Bank stocks also rose across the board, with Ruifeng Bank and CITIC Bank up over 1%.

Steel stocks performed strongly, with Anyang Steel and Jiu Steel Hongxing hitting the daily limit, while Zhongnan Shares and Lingang Shares saw significant gains.

Real estate stocks led the gains, with Beijing Energy Investment, Beijing Investment Development, and Zhongzhou Holdings hitting the daily limit.

The innovative drug sector strengthened, with San Sheng Guojian, Yuan Dong Biological, and Rongchang Biological rising over 6%; Zhaoyan New Drug’s stock price fell sharply, dropping over 9% in the early trading session, approaching the limit down.

42 stocks received leverage funding increases of over 100 million yuan each

As of March 16, the market financing balance totaled 2.64 trillion yuan, an increase of 9.74 billion yuan from the previous trading day.

Data shows that, specifically for individual stocks, on March 16, 1,905 stocks experienced net financing purchases, with 535 stocks having net buy-in amounts exceeding 10 million yuan, including 42 stocks with net buy-in amounts over 100 million yuan.

Baofeng Energy had the highest net financing buy-in, totaling 756 million yuan; followed by Cambrian and Yian Sheng, with net buy-ins of 603 million yuan and 510 million yuan respectively. Other stocks with high net buy-ins include Dongshan Precision, Buwei Storage, and Shudi Shares.

By industry, stocks with net financing buy-ins exceeding 100 million yuan are most concentrated in electronics, electrical equipment, and communications, with 13, 4, and 4 stocks respectively.

Leading innovative drug companies face large-scale shareholder reductions

On March 17, 24 companies announced plans for share reductions, with the highest proposed reduction ratios from Zhaoyan New Drug, Changqing Technology, Zongshen Power, and Keyuan Pharmaceutical.

Zhaoyan New Drug, a leading innovative drug company, announced a shareholder reduction plan. Shareholders Gu Xiaolei and his concerted parties plan to reduce 20.42 million and 10.32 million shares respectively within three months after the announcement, through centralized bidding, accounting for 4.1026% of the company’s current total shares. After the reduction, these two shareholders will no longer hold any shares in the company. The stock opened lower today and continued to decline, with a maximum drop of over 9%.

21 stocks experienced major shareholder reductions exceeding 100 million yuan each

Recent announcements show that, based on the date of shareholding changes, in the past five trading days (March 10–16), 94 companies saw significant shareholder reductions, totaling 292 million shares, with a combined reduction amount of 9.09 billion yuan.

In terms of amount, 21 companies had reductions exceeding 100 million yuan. The largest was Xinyuan Shares, which reduced a total of 4.4393 million shares, amounting to 926 million yuan.

Next was Shengke Communication-U, with a reduction of 4.1 million shares valued at 872 million yuan; Beijing Junzheng experienced shareholder reductions totaling 601 million yuan over the past five days, ranking third.

Disclaimer: All information from Data Treasure does not constitute investment advice. The stock market carries risks; invest cautiously.

Proofreading: Xu Xin